Lucideon says it has opened a dedicated U.S. biocompatibility laboratory in Greenville, South Carolina, adding testing capacity for medical devices and biomaterials. The facility will support cytotoxicity, extractables and leachables, toxicological risk assessment, surface characterization and other regulatory testing services.
Lucideon says it has opened a dedicated U.S. biocompatibility laboratory in Greenville, South Carolina, adding new testing capacity for medical devices and biomaterials.
The company said the site became operational in May 2026. It is intended to support patient safety and regulatory requirements by providing biocompatibility, cytotoxicity, extractables and leachables, toxicological risk assessment, surface characterization and related testing services.
Lucideon said the new facility complements its existing U.K. capabilities and expands its global testing infrastructure. The company framed the opening as part of its push to give medical device makers more local access to safety and compliance support in the United States.
The announcement was published on May 18, 2026, and was corroborated by Lucideon’s official website.
Revision note
Initial automated publication.